FAH Hospital Policy Blog

Perspectives on health policy affecting America's hospitals and the patients we serve.

CMMI | Health IT | Medicare | Regulatory Relief | Managed Care | 340B | FAH Policy Blog Team

FAH Recommends Deregulation Agenda to HHS

Today, FAH submitted comprehensive comments to the US Department of Health and Human Services (HHS) in response to its Request for Information (RFI): Ensuring Lawful Regulation and Unleashing Innovation To Make America Healthy Again, which seeks public input on how to dramatically deregulate across all areas of HHS.  FAH comments urged wide-ranging deregulatory initiatives, including those previously submitted to CMS in June, along with additional recommendations.  Key recommendations include, among others:

  • Oversight and compliance enforcement for Medicare Advantage plans.
  • Reject site-neutral cuts to Medicare.
  • Eliminate the inpatient rehabilitation facility Review Choice Demonstration.
  • Enforce the No Surprises Act Independent Dispute Resolution process.
  • Rescind interpretive guidance implying nurse staff ratio requirements.
  • Remove premature, low-value, and/or outdated hospital quality measures, as well as mandatory reporting for electronic clinical quality measures (eCQMs), along with requiring pre-deployment testing of hospital quality measures and reporting structures.
  • Right-size CMMI models and halt mandatory approaches.
  • Phase out or simplify the Promoting Interoperability Program.
  • Discontinue further development of the Merit-based Incentive Payment System (MIPS) Value Pathways (MVPs), while continuing with the Traditional MIPS program for measuring clinician performance.
  • Develop a more centralized model for public health reporting.
  • Remove CoP requirements for respiratory illness reporting and maternal health, while revising or updating CoPs for emergency services readiness and life safety codes.
  • Repeal provider disincentives for information blocking regulations.
  • Withdraw cybersecurity proposed regulations.
  • Expand eligibility for the 340B drug pricing program to tax-paying hospitals.

Read the full comment letter here.